NewEdge Wealth LLC Has $889,000 Holdings in Icon Plc $ICLR

NewEdge Wealth LLC grew its holdings in Icon Plc (NASDAQ:ICLR) by 81.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 8,038 shares of the medical research company’s stock after purchasing an additional 3,619 shares during the quarter. NewEdge Wealth LLC’s holdings in Icon were worth $889,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the business. Toth Financial Advisory Corp acquired a new position in Icon in the fourth quarter valued at approximately $27,000. EFG International AG acquired a new stake in Icon during the 4th quarter worth $27,000. Abound Financial LLC bought a new stake in shares of Icon during the 4th quarter valued at $54,000. Johnson Financial Group Inc. bought a new stake in shares of Icon during the 3rd quarter valued at $71,000. Finally, Quadrant Capital Group LLC acquired a new position in shares of Icon in the 3rd quarter valued at $78,000. Institutional investors and hedge funds own 95.61% of the company’s stock.

Icon Trading Up 1.8%

Shares of NASDAQ ICLR opened at $168.78 on Tuesday. Icon Plc has a twelve month low of $66.57 and a twelve month high of $203.91. The stock has a market cap of $12.92 billion, a price-to-earnings ratio of 30.03, a P/E/G ratio of 8.14 and a beta of 1.22. The company has a quick ratio of 1.14, a current ratio of 1.14 and a debt-to-equity ratio of 0.31. The company’s fifty day moving average is $152.21 and its 200-day moving average is $135.77.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Weiss Ratings lowered Icon from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, May 29th. Leerink Partners set a $145.00 price objective on Icon in a report on Thursday, May 28th. Royal Bank Of Canada raised Icon from a “sector perform” rating to an “outperform” rating and increased their target price for the company from $126.00 to $185.00 in a research note on Thursday, June 25th. Truist Financial upgraded Icon from a “hold” rating to a “buy” rating and raised their target price for the stock from $159.00 to $207.00 in a report on Tuesday, June 30th. Finally, Bank of America boosted their target price on Icon from $125.00 to $150.00 and gave the stock an “underperform” rating in a research report on Thursday, June 25th. Seven investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, Icon currently has an average rating of “Hold” and a consensus target price of $168.73.

Icon Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.